GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Allos Therapeutics, Inc. (ALTH) [hlAlert]

Rating:
Outperform
ALTH
down 76.01 %

Allos Therapeutics, Inc. (ALTH) rated Outperform with price target $11 by Leerink Swann

Posted on: Tuesday,  Jul 14, 2009  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Allos Therapeutics, Inc. (NASDAQ: ALTH) on 07/14/2009, when the stock price was $7.67.
Since then, Allos Therapeutics, Inc. has lost 76.01% as of 09/05/2012's recent price of $1.84.
If you would have followed this Leerink Swann 's recommendation on ALTH, you would have lost 76.01% of your investment in 1149 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/14/2009 8:25 AM Buy
None
7.67 11.00
as of 12/31/2009
1 Week down  -43.34 %
1 Month down  -44.04 %
3 Months down  -50.06 %
1 YTD down  -52.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy